Fennec Pharmaceuticals Board Changes

TL;DR

Fennec Pharma board chairman replaced, new guy in charge.

AI Summary

Fennec Pharmaceuticals Inc. announced on October 28, 2024, a change in its board of directors. Dr. David M. Levinson has been appointed as the new Chairman of the Board, succeeding Dr. Frederick W. Telling. The company also reported on compensatory arrangements for its officers.

Why It Matters

Changes in board leadership can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes can introduce uncertainty regarding strategic direction and operational continuity.

Key Players & Entities

• Fennec Pharmaceuticals Inc. (company) — Registrant
• Dr. David M. Levinson (person) — Newly appointed Chairman of the Board
• Dr. Frederick W. Telling (person) — Outgoing Chairman of the Board
• October 28, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $450,000 — annualized salary will be at a rate of $450,000, subject to review and increase from ti
• $400,000 — annualized salary will be at a rate of $400,000, subject to review and increase from ti
• $375,000 — annualized salary will be at a rate of $375,000, subject to review and increase from ti

Filing Documents

• tm2427086d1_8k.htm (8-K) — 38KB
• tm2427086d1_ex10-1.htm (EX-10.1) — 23KB
• tm2427086d1_ex10-2.htm (EX-10.2) — 24KB
• tm2427086d1_ex10-3.htm (EX-10.3) — 23KB
• tm2427086d1_ex99-1.htm (EX-99.1) — 25KB
• image_001.jpg (GRAPHIC) — 2KB
• 0001104659-24-112405.txt ( ) — 341KB
• fencf-20241028.xsd (EX-101.SCH) — 3KB
• fencf-20241028_lab.xml (EX-101.LAB) — 33KB
• fencf-20241028_pre.xml (EX-101.PRE) — 22KB
• tm2427086d1_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2024, Fennec Pharmaceuticals Inc.'s (the "Company") announced the appointments of Mr. Pierre S. Sayad, PhD, M.S., as Chief Medical Officer ("CMO"), Mr. Terry Evans as Chief Commercial Officer ("CCO"), and Ms. Christiana Cioffi, MBA, as Chief Strategy Officer ("CSO"), all of which became effective on October 28, 2024. There are no arrangements or understandings between each of Mr. Sayad, Mr. Evans, or Ms. Cioffi, and any other person pursuant to which such individual was appointed as CMO, CCO, and CSO, respectively. Neither Mr. Sayad, Mr. Evans, nor Ms. Cioffi have any family relationships with any other executive officer or director of the Company. None of these appointments have been involved in any related person transactions with the Company that would require disclosure under Item 404(a) of Regulation S-K. Dr. Sayad, age 50, is an accomplished biopharmaceutical executive with more than 22 years of proven success building and leading world-class organizations. During his tenure in the industry, Dr. Sayad has launched nine novel drugs across 14 therapeutic areas, including oncology (both solid tumors and hematologic malignancies) and neuroscience (depression, schizophrenia, bipolar, ADHD). Trained as a molecular physiologist, Dr. Sayad has been heavily involved in the successful commercial launches of several drugs, including oncology drugs at Onyx Pharmaceuticals, Karyopharm Therapeutics, Oncopeptides, and CTI Biopharma with respect to Kyprolis, Xpovio, Pepaxto, and Vonjo, respectively, as well as Eli Lilly and Company's blockbuster neuroscience drugs Zyprexa, Cymbalta, and Strattera. He also served as Senior Vice President, Business Development and Global Medical Affairs at the International Myeloma Foundation. Earlier in his career, Dr. Sayad was a strategic management consultant for Cam

01

Item 8.01. Other Items. On October 28, 2024, the Company issued a press release announcing the appointments of Mr. Sayad as CMO, Mr. Evans as COO, and Ms. Cioffi as CSO. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 8.01, including the press release attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 10.1 Executive Employment Agreement between the Company and Pierre Sayad, effective as of October 28, 2024 Exhibit 10.2 Executive Employment Agreement between the Company and Terry Evans, effective as of October 28, 2024 Exhibit 10.3 Executive Employment Agreement between the Company and Christiana Cioffi, effective as of October 28, 2024 Exhibit 99.1 Press Release dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date October 30, 2024 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR